Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?

SIMPLE SUMMARY: The historical standard treatment of metastatic non-small cell lung cancer (NSCLC) consisted of palliative chemotherapy, with limited influence on survival. With the introduction of immuno- and targeted therapy, the prognosis improved largely. A subset of NSCLC patients with limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Peeters, Stephanie T. H., Van Limbergen, Evert J., Hendriks, Lizza E. L., De Ruysscher, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125691/
https://www.ncbi.nlm.nih.gov/pubmed/33925139
http://dx.doi.org/10.3390/cancers13092132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125691/
https://www.ncbi.nlm.nih.gov/pubmed/33925139
http://dx.doi.org/10.3390/cancers13092132

Ejemplares similares